Hanmi Pharmaceutical at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Hanmi Pharmaceutical brings 3 presentations to ENA 2026 in Barcelona. Its posters cover engineered mRNA analogs and oral protein degraders as targeted cancer therapies. They include p53 mRNA analogs that restore tumor suppressor function in TP53-mutant cancers, a STING mRNA analog that acts through both immune activation and the tumor itself, and orally bioavailable EP300-selective degraders.
| Organization | ENA 2026 Attendance |
|---|---|
Hanmi Pharmaceutical Seoul, South Korea | |
Pharmaceutical company with marketed medicines and an R&D pipeline in oncology, obesity and metabolic disease. | Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm |
Instantly find 20 buyers from Hanmi Pharmaceutical
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction